EGI
ADMA icon

EAM Global Investors’s ADMA Biologics ADMA Stock Holding History

EAM Global Investors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-277,151
Closed -$4.75M – 83
2024
Q4 		$4.75M Sell
277,151
-126,820
-31% -$2.39M 0.85% 58
2024
Q3 		$8.08M Sell
403,971
-257,018
-39% -$4M 1.63% 6
2024
Q2 		$7.39M Sell
660,989
-110,574
-14% -$928K 1.66% 8
2024
Q1 		$5.09M Buy
+771,563
New +$4.22M 1.18% 34
2023
Q4 		– Sell
-632,352
Closed -$2.26M – 103
2023
Q3 		$2.26M Buy
+632,352
New +$2.43M 0.61% 91
2023
Q1 		– Sell
-836,323
Closed -$3.24M – 84
2022
Q4 		$3.24M Hold
836,323
– – 0.84% 26
2022
Q3 		$2.03M Hold
836,323
– – 0.54% 68
2022
Q2 		$1.66M Buy
+836,323
New +$1.65M 0.41% 117

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return

EAM Global Investors's ADMA Position: Q1 2025 in Review

EAM Global Investors sold out of ADMA Biologics (ADMA) in Q1 2025, closing a stake of 277,151 shares — an estimated $4.75M sold.

EAM Global Investors first reported a position in ADMA in Q2 2022 and held it in 8 quarters. The position peaked at $8.08M in Q3 2024. 347 funds tracked by Wall St. Rank hold ADMA as of Q1 2025.

  • EAM Global Investors reported no remaining ADMA Biologics position as of Q1 2025 after selling out during the quarter.
  • EAM Global Investors sold 277,151 ADMA Biologics shares in Q1 2025, an estimated $4.75M.
  • EAM Global Investors first reported a position in ADMA Biologics in Q2 2022 and held it in 8 quarters.
  • EAM Global Investors's ADMA Biologics position peaked at $8.08M in Q3 2024.
  • 347 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2025.

Based on EAM Global Investors's 13F filing for Q1 2025, filed 12 May 2025.